Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 1996

View Archived Issues

Takeda claims new treatments for pancreatitis

Regeneron claims novel use for neurotrophic factor

Schering-Plough claims novel use for Flt3 ligand

New antithrombotic agents described by Pfizer

New antiplatelet drugs from Takeda

LHRH antagonists under study at Takeda

Boehringer Ingelheim's modified anti-ICAM-1 antibodies for inflammatory disorders

Agents for urinary incontinence reported by Dainippon

NIH HIV immunoassay licensed to IGEN

QLT signs European licensing agreement for photosensitizer

Biomerica and Bentley sign marketing and distribution agreement

Biomatrix-Boehringer Ingelheim Synvisc agreement

Third approval for Parke-Davis HMG-CoA reductase inhibitor

Anti-CD2 MAb enters phase II for GVHD

ALRT-1550 to enter clinical trials

Additional filings and positive clinical results for Zadaxin

First Rx for oral ulcers cleared by FDA

Sanofi Winthrop returns diagnostics imaging rights to Nycomed

ImClone and Immunex crosslicense flt3/flk-2 technology

LIDAK develops drug discovery approach for asthma

Northwest Neurologic and Wyeth-Ayerst neurodegenerative disorder collaboration

Forest cleared to market new treatment for cystitis

IND filed for Cytel HIV therapeutic vaccine

Algos and Interneuron codevelop novel antimigraine combination

Androsorb cleared for clinical trials

Immunomedics files for approval of imaging agent for infectious disease

NanoSystems to develop novel formulation of HIV protease inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...